A tumour sequencing test approved in July 2026 as a companion diagnostic that finds BRAF V600E or V600K in melanoma, the mutations BRAF-targeted drugs act on.
Personal Genome Diagnostics, Inc. received FDA approval for PGDx elio tissue complete CDx on 30 July 2026 (PMA P250036). The FDA approval statement describes a qualitative, hybridisation-capture sequencing test on tumour tissue DNA that detects single-nucleotide variants, small insertions and deletions, copy number amplifications and translocations, intended as a companion diagnostic in melanoma. The FDA companion diagnostic list gives its claim as identifying melanoma with BRAF V600E and V600K for two groups of medicines approved by the FDA for that indication. The BRAF inhibitors it lists are dabrafenib (Tafinlar) and vemurafenib (Zelboraf); the BRAF and MEK inhibitor combinations it lists are cobimetinib (Cotellic) with vemurafenib, encorafenib (Braftovi) with binimetinib (Mektovi), and dabrafenib with trametinib (Mekinist).
Hybridisation-capture next-generation sequencing of DNA from formalin-fixed, paraffin-embedded tumour tissue; the targeted panel detects single-nucleotide variants, small insertions and deletions, copy number amplifications and translocations. Connects to BRAF.
| Where | Who pays | Help with the cost | |
|---|---|---|---|
| 🇺🇸 United States | Approved 2026 | - | - |
Approval is the regulator's decision for any cancer indication, with the year of the first; it is not a promise that a hospital stocks the drug or that your indication is covered. Not recorded for European Union, United Kingdom, Japan, China, Australia, India: a gap in our research, not a refusal. Compare products across regions.
| Region | Year | Indication |
|---|---|---|
| US | 2026 | BRAF V600E and V600K in melanoma, for BRAF inhibitors and BRAF and MEK inhibitor combinations approved by the FDA for that indication (group labelling) |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"PGDx elio tissue complete CDx" OR ABSTRACT:"PGDx elio tissue complete CDx") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PGDx elio tissue complete CDx, not a curated reading list.
Shares Companion diagnostic, Companion diagnostics, Next-generation sequencing (NGS) and the tag test.
Shares Companion diagnostic, Companion diagnostics, Next-generation sequencing (NGS) and the tag test.
Shares Companion diagnostic, Companion diagnostics, Next-generation sequencing (NGS) and the tag test.
Shares Companion diagnostic, Companion diagnostics, Next-generation sequencing (NGS), BRAF and the tag test.
Shares Companion diagnostic, Companion diagnostics and the tag test.
Shares Companion diagnostic, Encorafenib, Companion diagnostics, BRAF and the tag test.
Shares Companion diagnostic, Companion diagnostics and the tag test.
Shares Companion diagnostic, Companion diagnostics and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/